Trial
NCT04803201
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Phase IISUSPENDEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Alliance for Clinical Trials in Oncology
Collaborators
National Cancer Institute (NCI)
Condition
Angioimmunoblastic T-cell Lymphoma
Intervention
Cyclophosphamide
Why stopped
Interim Analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-02